DOXEPIN HYDROCHLORIDE | A201951 | ACTAVIS ELIZABETH LLC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Somaxon Pharmaceuticals Inc. et al v. Actavis Elizabeth LLC et al 1 patentANDA 201951, 202337doxepin hydrochloride | D. Del. | 2010-12-15 | Terminated 2022-10-03 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$1.59
per ea
Lowest NADAC/Unit
$1.36
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00228331603DOXEPIN HCL 6 MG TABLET | $1.59 | EA | Generic | — | 2026-06-17 |
| 00228331503DOXEPIN HCL 3 MG TABLET | $1.36 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.